CSIMarket
 


Lucira Health Inc   (LHDX)
Other Ticker:  
 

Cumulative Lucira Health Inc 's Working Capital Ratio for Trailing Twelve Months Period

LHDX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

LHDX Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Growth 192.33 % 94.67 % 295.69 % - -
Y / Y Current Assets Growth -37.54 % 2.13 % 17.22 % - -
Working Capital Ratio for Trailing Twelve Months Period 3.17 4.35 5 6.76 8.59
Total Ranking # 1553 # 1361 # 1236 # 933 # 749
Seq. Current Liabilities Growth 43.88 % -18.68 % 36.19 % 83.45 % -4.19 %
Seq. Current Assets Growth -45.37 % -15.21 % 26.09 % 6.96 % -10.68 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2022
On the trailing twelve months basis Due to jump in Current Liabilities in the III. Quarter to $80 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 3.17 below Lucira Health Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within In Vitro & In Vivo Diagnostic Substances industry 18 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Lucira Health Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about LHDX
Working Capital Ratio LHDX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 19
Sector # 988
S&P 500 # 2911


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
6.74 5.16 3.1
(Dec 31 2021)   (Sep 30 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2022, within In Vitro & In Vivo Diagnostic Substances Industry Working Capital Ratio for Trailing Twelve Months Period
Heska Corporation  7.39 
Intellia Therapeutics Inc   6.98 
Achieve Life Sciences Inc   6.60 
Immucell Corp  6.51 
Mymd Pharmaceuticals Inc   5.75 
Aspira Women s Health Inc   4.70 
Biomerica Inc   4.00 
Meridian Bioscience Inc   3.80 
Quotient Limited  3.58 
Lucira Health Inc   3.46 
Oncocyte Corporation  3.16 
Myriad Genetics Inc   2.46 
Quidelortho Corp  2.34 
Lantheus Holdings Inc   2.16 
Ortho Clinical Diagnostics Holdings Plc  1.83 
Volitionrx Limited  1.77 
Cardio Diagnostics Holdings Inc   1.24 
Idexx Laboratories Inc  1.10 
Trinity Biotech Plc  1.01 
Navidea Biopharmaceuticals Inc   0.83 
Nymox Pharmaceutical Corporation  0.64 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com